Testing the Ability of Pembrolizumab to Alter the Tumor Immune MicroEnvironment (TIME) of High Risk DCIS
Phase of Trial: Phase 0
Latest Information Update: 28 Jun 2018
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 19 Jun 2018 Planned End Date changed from 1 Sep 2018 to 1 Sep 2019.
- 19 Jun 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2019.
- 18 Apr 2018 Results presented at the 109th Annual Meeting of the American Association for Cancer Research